Drug therapy to reduce early readmission risk in heart failure: ready for prime time?

Abstract	Readmission for heart failure remains a major focus of policymakers, clinicians, and patients. Despite meeting key national performance measures and frequent use of evidence-based therapies, rates of 30-day post-discharge rehospitalization may be as high as 25%. Digoxin and mineralocorticoid antagonists are known to reduce admissions for heart failure, but are significantly underused in current clinical practice despite their proven benefits.
Authors	Muthiah Vaduganathan, Gregg C Fonarow, Mihai Gheorghiade
Journal	JACC. Heart failure (JACC Heart Fail) Vol. 1 Issue 4 Pg. 361-364 (Aug 2013) ISSN: 2213-1787 [Electronic] United States
PMID	24621940 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Copyright	Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Chemical References	Cardiotonic Agents Mineralocorticoid Receptor Antagonists Digoxin
Topics	Cardiotonic Agents (therapeutic use) Digoxin (therapeutic use) Heart Failure (drug therapy) Humans Mineralocorticoid Receptor Antagonists (therapeutic use) Patient Readmission (statistics & numerical data) Risk Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!